Cellular Products Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cellular Products Inc.
EMA seeks industry views on drug-or-device proposals
The European Medicines Agency wants industry's views on what makes an advanced therapy an 'advanced therapy.' It has issued for public consultation a reflection paper on the classification of advanced therapy medicinal products (30 April 2012).
US FDA outlines regulatory science strategy
The US FDA last week unveiled its comprehensive plan to update the applied science used in developing the tools, standards and approaches for assessing the safety, efficacy quality, and performance of FDA-regulated products, including prescription drugs.
Executive Briefing - Getting to grips with advanced therapies in the EU
It is now almost a year since new EU rules on the development, evaluation and approval of advanced therapies came into effect. Ian Schofield assesses progress so far and looks at which kinds of products are likely to be coming through the system over the next few years.
Celsis to be acquired by US investment firm
Celsis International, the UK life sciences products and laboratory services company, is to be acquired by the private equity company Nastor Investments for around 232.5 pence per share.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice